Introduction
The interest for a therapeutic use of branched-chain amino acids (BCAAs) continued to increase during the last few years because of their peculiar role in wholebody metabolism. BCAAs are not only a substrate for protein synthesis, but also modulate several components of the synthetic machinery and help to conserve muscle mass [1] . Among the BCAAs, leucine is of particular interest.
Two mechanisms of action may account for the beneficial effects of BCAAs. First, their regulatory activity on total body nitrogen metabolism may help to improve nitrogen balance. Different pathological/physiological conditions, characterized by protein loss and catabolic status, are likely to benefit from amino acid administration. Secondly, the competitive action of BCAAs on amino acid transport across the blood-brain barrier may ultimately alter the synthesis of epinephrine, norepinephrine, dopamine and serotonin in the nervous system, thus altering neurotransmission. This action has been used to improve neurotransmission in neurological diseases.
In the last few years, several trials tried to evaluate the efficacy of amino acid administration in different settings. We shall revise the results obtained in metabolic and critical (post-traumatic and/or post-surgical) conditions, as well as in neurological and psychiatric disorders, with contrasting results (Table 1) .
BCAAs as nutritional agents
Different pathological/physiological conditions, characterized by protein loss and catabolic status, are likely to benefit from BCAA administration, but their role in comparison to standard amino acid solution or dietary proteins is uncertain.
Muscle performance
After a bout of energy expenditure, there is an increased abundance of mRNA encoding a number of proteins [15] . Endurance exercise results in a net increase in a number of mitochondrial enzymes [16] and in an increase of mixed muscle protein synthesis [17] . Endurance exercise thus increases the amount of amino acid needed to satisfy the increased tissue requirements, but the type of protein/amino acid needed to fulfill this requirement is a matter of discussion. Low-to moderateintensity endurance exercises do not negatively affect protein or amino acid balance and, provided that the energy intake is adequate, this condition is accompanied by a consensual increase in the use of amino acid pool [18] . In moderate-intensity exercise, protein balance is slightly negative in subjects who consume a 1.0 g/kg daily protein diet and positive in those who increase their protein intake to 2.5 g/kg [19] . In the high protein diet group, CHO storage and fat oxidation are greater. The effects of BCAAs on energy metabolism and muscle performance have been recently re-evaluated [2 . ]. In a double-blind, crossover and placebo-controlled acute experimental set-up, 12 healthy subjects were administered orally either BCAAs (14.4 g/day) or isocaloric placebo on two consecutive days; in a chronic study, 10 healthy subjects received BCAAs (14.4 g/day) for 30 days. Acute BCAA supply produced a greater and longer-lasting increase in oxygen consumption and respiratory quotient, without excess thermogenesis. Subjects on chronic BCAAs showed a significant increase in the maximal strength of forearm muscle, possibly related to the anabolic action of BCAAs. In summary, in untrained healthy humans, BCAA supplementation improves physical fitness via a eutrophic effect on body composition and on muscle contractility, unrelated to training.
Weight loss
The effects of BCAA supplements on whole-body and muscle metabolism suggest a positive action of BCAAs in subjects consuming reduced caloric diets. The stimulation of protein muscle synthesis and the modulation of insulin-signaling pathway [20] [21] [22] by BCAAs can preserve bodily proteins during a nutritional treatment in obese patients. Layman et al. [4 . . ] evaluated the effects of sustained dietary changes in the ratio of carbohydrate (CHO) to protein intake on plasma amino acid profiles and on maintenance of blood glucose in women consuming a hypocaloric diet. Twenty-four women were assigned either to a protein group (9.9 g of leucine and 22.3 g of BCAAs per day; CHO540%) or CHO group (5.4 g of leucine and 12.3 g of BCAAs per day; CHO4 55%). After 10 weeks, the protein and the CHO groups had similar weight loss, but subjects in the CHO group had a lower fasting and post-prandial blood glucose concentration and elevated insulin level following meal consumption. Associated with the reduced blood glucose, subjects in the CHO group had combined alanine plus glutamine levels that were 20% higher than those of the protein group, tentatively related to increased rates of protein breakdown and a reduced hepatic clearance. These results confirm that a diet low in CHO and rich in proteins (namely BCAAs) stabilizes blood glucose during non-absorptive periods and reduces post-prandial insulin response, preventing hypoglycemia and a secondary activation of gluconeogenesis.
Immobilization and space-flight syndromes
Space flight is characterized by loss of protein from the weight-bearing muscles, which persists throughout the early post-flight period [23] . Damages are proportional to the duration of the mission, as, in space flight, protein synthesis is suboptimal. BCAA levels are reduced in the immediate post-flight phase and low levels persist during the first week of recovery [24] .
Bed rest may be used to simulate the muscolo-skeletal response to space flight. Stuart et al. [25] previously demonstrated that bed rest is associated with a decrease in whole-body protein synthesis rate. Increasing the protein content of the diet during space flight/bed rest can prevent or reduce nitrogen losses. In a recent study, Stein et al. [6 . . ] compared BCAA supplementation (30 mmol/day each of leucine, isoleucine and valine) to a mixture of non-essential amino acids (30 mmol/day each of glycine, serine and alanine) in bed-rested patients. The study was divided into three phases: a 1-day ambulatory period (baseline), a 14-day bed-rest period (when patients were not allowed to move from the bed) and a 4-day recovery period in which patients could just walk around the clinic area. Whole-body protein synthesis and breakdown were reduced by *20% during both experimental periods. During bed rest, nitrogen retention was greater with BCAA feeding and the concentration of free amino acids in muscle biopsies was increased. No effects were found on either whole-body, muscle or plasma protein synthesis. In the recovery phase, the BCAA group showed a significant reduction in total glucose production and in gluconeogenesis from alanine. In conclusion, the supplementation of the diet with BCAAs produces nitrogen accretion in the free amino acid pool, but is not effective in . Spinocerebellar degeneration [7] .
Traumatic patients [8] .
Chronic heart failure [9] .
Liver disease [10 . . ,11 . . , 12 . ,13 . , 14] promoting protein synthesis. However, the availability of additional essential amino acids might produce beneficial effects in the recovery phase.
Traumatic patients
The catabolic state of trauma patients after an operation includes negative protein balance, changes in plasma amino acid levels, leading to acute protein malnutrition, decline of immunological competence and dysfunction of multiple organs. BCAAs decrease the degradation of visceral proteins, prevent amino acid loss from muscle, correct negative balance, improve protein synthesis and regulate serum amino acid levels. In a prospective, randomized, single-blind controlled study, 40 adult patients, who had an abdominal operation and needed total parenteral nutrition (TPN) received either a conventional amino acid formula or a BCAA-enriched formula for 6 days [8] . The negative nitrogen balance significantly improved after TPN. The BCAA group reached a positive nitrogen balance 2 days earlier than the conventional group and nitrogen balance was significantly better. In the BCAA group, total protein and albumin levels more markedly increased -a beneficial effect on nutritional status, secondarily reducing the recovery period.
Chronic heart failure Non-obese, free-living patients with clinically stable chronic heart failure have an inadequate intake of calories and protein, resulting in negative energy and nitrogen balance, resulting in 41% lower energy availability for physical activity [26] . BCAAs exert anabolic actions on heart protein metabolism, and their uptake by the myocardium is largely dependent on plasma concentrations. In the heart muscle tissue, BCAAs diminish myocardial lactate and, in the ischemic heart, the defects generated by lactate accumulation may be overridden. A short-term infusion of BCAAs showed an anabolic effect on heart protein metabolism [27] . This might be mainly the case in subjects with diabetes, who are at high risk of chronic heart failure and in whom altered BCAA levels are frequently reported [9] . This is an area of research deserving future studies.
Liver disease
This is traditionally the most interesting area for BCAA use. The effects of BCAA supplements are not only mediated by their regulatory action on protein metabolism, but a specific role for BCAAs in the prevention of hepatic encephalopathy has long been advocated, via regulation of neurotransmitter synthesis.
Both issues have long been debated, and several review articles or meta-analyses are available [28, 29] . A comprehensive Cochrane review has also been published [10 . . ]. The final conclusion of the reviewers was that there was no convincing evidence in favor of BCAAs over other nutritional sources in cirrhosis with hepatic encephalopathy. However, the authors remarked on the lack of long-term studies having an adequate power to detect differences.
In a large randomized, controlled trial, 1-year BCAA supplements were compared with equicaloric (maltodextrins) or equicaloric/equinitrogenous supplements (lactoalbumin) in 174 patients with advanced cirrhosis [11 . . ]. BCAA supplementation significantly decreased the combined event rate (death or progression to liver failure) compared with lactoalbumin (OR, 0.43; 95% Confidence Interval, 0.19-0.96; P = 0.039) and nonsignificantly compared with maltodextrins (OR, 0.51; 95% CI, 0.23-1.17; P = 0.108). Also, the average hospital admission rate was lower in the BCAA arm compared with both control treatments (P = 0.006 and P = 0.003, respectively). In patients who remained in the study, nutritional parameters, predictors of long-term survival, and liver function tests were, on average, stable or improved during BCAA treatment, and the Child-Pugh score decreased (P = 0.013). Also, anorexia and healthrelated quality of life (Short Form-36 questionnaire) improved.
Similar results were obtained in patients undergoing chemoembolization for hepatocellular carcinoma [12 . ]. The administration of BCAA supplements lowered overall morbidity, reduced the prevalence of ascites and peripheral edema, increased serum albumin and improved quality of life, without differences in survival.
Other recent studies focused on timing of BCAA supply to reach the target effects. Following the pioneering studies of Swart et al. [30] , Fukushima et al. [13 . ] tested the usefulness of night-time BCAA supplementation for a week in a crossover study in 12 patients with cirrhosis. Another 12 patients who did not respond to day-time administration were randomly assigned to either nocturnal or day-time long-term supplementation. Day-time administration improved nitrogen balance, but the results were somewhat better during nocturnal supplementation. In the long term, a significant increase in serum albumin (by approximately 10%) was only observed in patients administered nocturnal BCAAs, which are expected to produce a better nitrogen accretion, favoring protein synthesis. These data are in keeping with the idea that cirrhotic patients have an accelerated fasting, favoring protein catabolism, which can be reversed by a late evening meal or nocturnal BCAA supplementation [13 . ].
Candidates for orthotopic liver transplantation are a specific setting for BCAA use. Most patients enter the waiting list with profound disturbances in amino acid levels, which are only partially normalized by the transplant. In particular, BCAA levels remain low, indicating a possible, persistent change in muscular amino acid metabolism, which requires adequate treatment [14] .
The beneficial effects of BCAAs in a variety of liver disease raised questions as to the mechanism of improved liver function. Positive nitrogen balance may favor protein synthesis in tissues and organs outside skeletal muscle, including the liver parenchyma. Studies with liver resection in experimental animals and humans suggest that the regenerative response is dependent on several circulating factors, including hepatocyte growth factor (HGF) -a pleiotropic substance with mitogenic activity [31] . Recent studies have shown that BCAAs, namely leucine, are a potent stimulator of HGF secretion by hepatic stellate cells [32] . Accordingly, the prevention of liver failure observed in patients with advanced cirrhosis during BCAA supplementation might stem from increased liver regeneration, compensating for progressive liver cell death.
BCAA as regulators of neurotransmitter synthesis
The competitive action of BCAAs for blood-brain amino acid transport is the basis for their alleged effect on the synthesis of neurotransmitters. The entry of aromatic amino acids and tryptophan in the cerebrospinal fluid may be regulated by BCAA, reducing the synthesis of epinephrine, norepinephrine, dopamine and serotonin in the nervous system.
Mania
Bipolar disorders may stem from a variety of factors, namely genetic, chemical, social and psychological, which contribute to deregulate the diencephalic functions (limbic system). Different neurotransmitters (norepinephrine, serotonin, dopamine, g-aminobutyrric acid) are involved in mood regulation. A prevalence of noradrenergic transmission over cholinergic systems was demonstrated in manic hyperactivation [33] , which is expected to ameliorate following tyrosine depletion.
McTavish et al. [34] showed that a single dose of tyrosine-free amino acid load in manic patients decreases symptoms by 35%. Blood tyrosine depletion leads to a decrease in noradrenergic synthesis and to a reduction of dopamine function, which can explain the BCAA effects on manic disorders. In a recent placebocontrolled randomized study, 25 manic patients were treated with 60 g of valine, isoleucine and leucine drink in the ratio 3:3:4 or with a placebo with similar consistency and taste. The BCAA drink lowered mania ratings acutely over the first 6 h of treatment, but longterm effects were not different between groups [3 . . ].
In general, there was a waning of the effects in the placebo group, and a continued improvement in the BCAA group, which reached statistical significance by day 15. In summary, this pilot study opens a new area for BCAA use.
Tardive dyskinesia
Phenylketonuria and high plasma and brain levels of phenylalanine have been identified as risk factors for tardive dyskinesia [35] . The supplementation of the diet with BCAAs decreases the concentration of aromatic amino acids in plasma, by the stimulation of protein synthesis (primarily in muscle), by suppressing their flux from muscle into plasma, and finally by competition on blood-brain-barrier transport systems. This is expected to decrease the central synthesis of the neurotransmitters, dopamine, norepinephrine and serotonine. In a placebo-controlled trial, the efficacy of BCAAs (222 mg/ kg of body weight three times daily) 3 weeks into the treatment of tardive dyskinesia has been tested in 36 subjects with psychiatric disorders [5 . . ]. Symptoms were reduced within 1 week, as soon as plasma aromatic amino acid concentrations declined. Minimal gastrointestinal symptoms occurred during the trial. Given the effect of BCAA supplementation on plasma levels of phenylalanine, it can also be suggested that BCAAs may have a positive effect in the treatment of phenylketonuric patients, either in the prevention or in the therapy of neurological alterations.
Spinocerebellar degeneration
Glutamate is important for neurotransmission between the cerebellar granule cells and Purkinje cells. Stimulation of intracellular glutamate metabolism might improve neurotransmission among cerebellar neurons [36] , and BCAAs are the major nitrogen source for glutamine and alanine synthesis. In a double-blind crossover study, Mori et al. [7] investigated the effect of BCAA supplementation in patients with spinocerebellar degeneration -a condition mainly characterized by ataxia. Sixteen patients were assigned to receive a supplementation of BCAAs, in a random order and at different doses (from 1.5 to 6.0 g), or placebo for 4 weeks on a double-blind basis. Supplementation was given orally before meals, three times a day throughout the study period. Ataxia degree was evaluated through the International Cooperative Ataxia Rating Scale (ICARS). Since BCAAs compete with levodopa for transport across the blood-brain barrier, patients with marked Parkinsonian symptoms (rigidity and akinesia) were not enrolled in the trial. BCAA treatment produced a global improvement of cerebellar symptoms. Global ICARS scores were significantly improved, especially in patients who received treatment at intermediate doses, but the reason why middle dose exerts the highest effects remains unknown.
Conclusion
Evidence supporting a beneficial role for BCAAs in treating a variety of diseases has accumulated over the past 30 years, and continues to grow each year. New areas for their use, both as regulators of protein metabolism and as regulators of neurotransmitter synthesis, are emerging. We need long-term, randomized clinical studies, both in the prevention and in the treatment of various pathological conditions. These studies, as the recent BCAA trial in cirrhosis showed [11 . . ], are extremely difficult to perform, but they are the only way to improve our standard of care. The study raises doubts as to the possible benefits of increased BCAA supply during space flights or in the early post-mission phase, since the amount of nitrogen accreted is not enough to impact protein kinetics.
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